Gp130 degradation induced by epirubicin contributes to chemotherapy efficacy
Copyright © 2019 Elsevier Inc. All rights reserved..
Two anthracyclines, doxorubicin and epirubicin have been widely used alone or in combination with other antitumor reagents in the chemotherapeutic treatment of various malignancies. Although therapeutic efficacy of anthracyclines has been studied extensively, precise cytotoxic mechanism of these drugs is not been completely elucidated. Here we show that epirubicin-induced degradation of transmembrane protein gp130 contributes to antitumor effect of epirubicin. gp130 is degraded by epirubicin in a proteasome- and autophagy-dependent manner. Epirubicin induces activation of p38-MK2 signaling pathway to phosphorylate gp130 at Ser 782, which results in gp130 internalization and degradation by lysosome. Although mutation of Ser 782 to Ala or Cys in gp130 upregulates global epirubicin-induced autophagy, reduced degradation of gp130 accompanied with enhanced Stat3 phosphorylation at tyrosine 705 is observed. We also show that epirubicin-resistant tumor cells express higher level of gp130. Altogether, our results indicate that degradation of gp130 and subsequent reduction of gp130-Stat3 signaling contributes to epirubicin-induced tumor cell death.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:519 |
|---|---|
| Enthalten in: |
Biochemical and biophysical research communications - 519(2019), 3 vom: 12. Nov., Seite 572-578 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Liu, Fangming [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 29.06.2020 Date Revised 29.06.2020 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.bbrc.2019.09.055 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM301454213 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM301454213 | ||
| 003 | DE-627 | ||
| 005 | 20231225104645.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.bbrc.2019.09.055 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1004.xml |
| 035 | |a (DE-627)NLM301454213 | ||
| 035 | |a (NLM)31537377 | ||
| 035 | |a (PII)S0006-291X(19)31776-0 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Liu, Fangming |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Gp130 degradation induced by epirubicin contributes to chemotherapy efficacy |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.06.2020 | ||
| 500 | |a Date Revised 29.06.2020 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2019 Elsevier Inc. All rights reserved. | ||
| 520 | |a Two anthracyclines, doxorubicin and epirubicin have been widely used alone or in combination with other antitumor reagents in the chemotherapeutic treatment of various malignancies. Although therapeutic efficacy of anthracyclines has been studied extensively, precise cytotoxic mechanism of these drugs is not been completely elucidated. Here we show that epirubicin-induced degradation of transmembrane protein gp130 contributes to antitumor effect of epirubicin. gp130 is degraded by epirubicin in a proteasome- and autophagy-dependent manner. Epirubicin induces activation of p38-MK2 signaling pathway to phosphorylate gp130 at Ser 782, which results in gp130 internalization and degradation by lysosome. Although mutation of Ser 782 to Ala or Cys in gp130 upregulates global epirubicin-induced autophagy, reduced degradation of gp130 accompanied with enhanced Stat3 phosphorylation at tyrosine 705 is observed. We also show that epirubicin-resistant tumor cells express higher level of gp130. Altogether, our results indicate that degradation of gp130 and subsequent reduction of gp130-Stat3 signaling contributes to epirubicin-induced tumor cell death | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Autophagy | |
| 650 | 4 | |a Epirubicin | |
| 650 | 4 | |a Lung cancer | |
| 650 | 4 | |a Phosphorylation | |
| 650 | 4 | |a gp130 | |
| 650 | 4 | |a p38 | |
| 650 | 7 | |a Antibiotics, Antineoplastic |2 NLM | |
| 650 | 7 | |a Cytokine Receptor gp130 |2 NLM | |
| 650 | 7 | |a 133483-10-0 |2 NLM | |
| 650 | 7 | |a Epirubicin |2 NLM | |
| 650 | 7 | |a 3Z8479ZZ5X |2 NLM | |
| 650 | 7 | |a Proteasome Endopeptidase Complex |2 NLM | |
| 650 | 7 | |a EC 3.4.25.1 |2 NLM | |
| 700 | 1 | |a Jin, Haizhen |e verfasserin |4 aut | |
| 700 | 1 | |a Shen, Jinhong |e verfasserin |4 aut | |
| 700 | 1 | |a Wu, Dan |e verfasserin |4 aut | |
| 700 | 1 | |a Tian, Ye |e verfasserin |4 aut | |
| 700 | 1 | |a Huang, Chao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Biochemical and biophysical research communications |d 1960 |g 519(2019), 3 vom: 12. Nov., Seite 572-578 |w (DE-627)NLM000000035 |x 1090-2104 |7 nnns |
| 773 | 1 | 8 | |g volume:519 |g year:2019 |g number:3 |g day:12 |g month:11 |g pages:572-578 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.bbrc.2019.09.055 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 519 |j 2019 |e 3 |b 12 |c 11 |h 572-578 | ||